Lyndra Therapeutics

About Lyndra Therapeutics

Lyndra Therapeutics is a company focused on reinventing medicine through the development of long-acting oral therapies. Their mission is to transform the patient experience by freeing people from the burden of daily pills, simplifying lives with innovations like the LYNX™ drug delivery platform. Founded in 2015 with technology from MIT's Langer Lab, Lyndra aims to bring these therapies to people with various health conditions.

Products & Services

LYNX™ Drug Delivery Platform:A transformative platform designed for long-acting oral therapies, allowing a week's worth of medicine in a single dose, with potential for broad applicability across multiple therapeutic areas.

Oral Weekly Risperidone (LYN-005):A long-acting oral therapy for schizophrenia, currently in clinical trials with positive Phase 3 study data announced.

Specialties

Long-acting oral therapies Drug delivery innovation Central Nervous System (CNS) treatments

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series E T: - FT: Series E	A: 101000000 MR: - FA: $101 million FAN: 101000000	D: 2023-12-21 FD: 2023-12-21	3 investors

Series E Latest

2023-12-21

$101.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Rosemary Kanasty

VP, Risperidone CMC Lead

R

Robert Langer

Founder

G

Giovanni Traverso

A

Andrew Bellinger

Co-Founder

A

Amy Schulman

Founder

J

Jessica Ballinger

President and CEO

View 3 more team members with Pro

Unlock Full Team Directory

Recent News